ALVOTECH SA (ALVO) Fundamental Analysis & Valuation

NASDAQ:ALVO • LU2458332611

Current stock price

3.405 USD
-0.1 (-2.71%)
Last:

This ALVO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ALVO Profitability Analysis

1.1 Basic Checks

  • ALVO had positive earnings in the past year.
  • ALVO had a negative operating cash flow in the past year.
  • In the past 5 years ALVO reported 4 times negative net income.
  • ALVO had a negative operating cash flow in each of the past 5 years.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M

1.2 Ratios

  • ALVO's Return On Assets of 1.88% is amongst the best of the industry. ALVO outperforms 88.18% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 5.22%, ALVO belongs to the top of the industry, outperforming 90.50% of the companies in the same industry.
Industry RankSector Rank
ROA 1.88%
ROE N/A
ROIC 5.22%
ROA(3y)-25.06%
ROA(5y)-30.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • Looking at the Profit Margin, with a value of 4.74%, ALVO belongs to the top of the industry, outperforming 89.15% of the companies in the same industry.
  • ALVO has a Operating Margin of 13.28%. This is amongst the best in the industry. ALVO outperforms 91.09% of its industry peers.
  • Looking at the Gross Margin, with a value of 60.00%, ALVO is in the better half of the industry, outperforming 76.74% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ALVO has grown nicely.
Industry RankSector Rank
OM 13.28%
PM (TTM) 4.74%
GM 60%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.59%
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ALVO Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALVO is destroying value.
  • ALVO has more shares outstanding than it did 1 year ago.
  • ALVO has more shares outstanding than it did 5 years ago.
  • ALVO has about the same debt/assets ratio as last year.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • Based on the Altman-Z score of -1.10, we must say that ALVO is in the distress zone and has some risk of bankruptcy.
  • ALVO has a Altman-Z score of -1.10. This is comparable to the rest of the industry: ALVO outperforms 52.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACC0.84
WACC6.22%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that ALVO should not have too much problems paying its short term obligations.
  • ALVO has a Current ratio of 1.89. This is in the lower half of the industry: ALVO underperforms 78.88% of its industry peers.
  • A Quick Ratio of 1.16 indicates that ALVO should not have too much problems paying its short term obligations.
  • ALVO's Quick ratio of 1.16 is on the low side compared to the rest of the industry. ALVO is outperformed by 84.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.16
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. ALVO Growth Analysis

3.1 Past

  • ALVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 108.05%, which is quite impressive.
  • The Revenue has grown by 19.70% in the past year. This is quite good.
  • ALVO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 53.35% yearly.
EPS 1Y (TTM)108.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.17%
Revenue 1Y (TTM)19.7%
Revenue growth 3Y90.62%
Revenue growth 5Y53.35%
Sales Q2Q%10.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 89.23% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 25.37% on average over the next years. This is a very strong growth
EPS Next Y167.14%
EPS Next 2Y163.55%
EPS Next 3Y89.23%
EPS Next 5YN/A
Revenue Next Year12.78%
Revenue Next 2Y15.67%
Revenue Next 3Y18.67%
Revenue Next 5Y25.37%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. ALVO Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 48.64, the valuation of ALVO can be described as expensive.
  • Based on the Price/Earnings ratio, ALVO is valued cheaply inside the industry as 90.12% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of ALVO to the average of the S&P500 Index (27.50), we can say ALVO is valued expensively.
  • Based on the Price/Forward Earnings ratio of 18.21, the valuation of ALVO can be described as rather expensive.
  • 94.96% of the companies in the same industry are more expensive than ALVO, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of ALVO to the average of the S&P500 Index (22.62), we can say ALVO is valued inline with the index average.
Industry RankSector Rank
PE 48.64
Fwd PE 18.21
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • ALVO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALVO is cheaper than 92.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.41
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • ALVO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ALVO's earnings are expected to grow with 89.23% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y163.55%
EPS Next 3Y89.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALVO Dividend Analysis

5.1 Amount

  • ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALVO Fundamentals: All Metrics, Ratios and Statistics

ALVOTECH SA

NASDAQ:ALVO (4/23/2026, 12:29:09 PM)

3.405

-0.1 (-2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)05-06
Inst Owners5.63%
Inst Owner Change0.01%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap1.06B
Revenue(TTM)588.90M
Net Income(TTM)27.92M
Analysts78.33
Price Target7.4 (117.33%)
Short Float %2.6%
Short Ratio5.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-425.6%
Min EPS beat(2)-706.1%
Max EPS beat(2)-145.1%
EPS beat(4)2
Avg EPS beat(4)29.57%
Min EPS beat(4)-706.1%
Max EPS beat(4)557.52%
EPS beat(8)5
Avg EPS beat(8)1035.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.61%
Min Revenue beat(2)-4.76%
Max Revenue beat(2)3.53%
Revenue beat(4)3
Avg Revenue beat(4)19.21%
Min Revenue beat(4)-4.76%
Max Revenue beat(4)41.02%
Revenue beat(8)5
Avg Revenue beat(8)12.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.14%
PT rev (3m)-17.14%
EPS NQ rev (1m)21.21%
EPS NQ rev (3m)21.21%
EPS NY rev (1m)-55.01%
EPS NY rev (3m)-55.01%
Revenue NQ rev (1m)-0.49%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)-17.81%
Revenue NY rev (3m)-22.35%
Valuation
Industry RankSector Rank
PE 48.64
Fwd PE 18.21
P/S 1.8
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 20.41
EPS(TTM)0.07
EY2.06%
EPS(NY)0.19
Fwd EY5.49%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS1.89
BVpS-0.91
TBVpS-1.22
PEG (NY)0.29
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 1.88%
ROE N/A
ROCE 6.61%
ROIC 5.22%
ROICexc 6.11%
ROICexgc 6.74%
OM 13.28%
PM (TTM) 4.74%
GM 60%
FCFM N/A
ROA(3y)-25.06%
ROA(5y)-30.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.59%
GM growth 5YN/A
F-Score2
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 12.06
Cap/Depr 253.97%
Cap/Sales 16.32%
Interest Coverage 1.33
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.16
Altman-Z -1.1
F-Score2
WACC6.22%
ROIC/WACC0.84
Cap/Depr(3y)209.34%
Cap/Depr(5y)218.29%
Cap/Sales(3y)25.89%
Cap/Sales(5y)47.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.17%
EPS Next Y167.14%
EPS Next 2Y163.55%
EPS Next 3Y89.23%
EPS Next 5YN/A
Revenue 1Y (TTM)19.7%
Revenue growth 3Y90.62%
Revenue growth 5Y53.35%
Sales Q2Q%10.14%
Revenue Next Year12.78%
Revenue Next 2Y15.67%
Revenue Next 3Y18.67%
Revenue Next 5Y25.37%
EBIT growth 1Y12.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year113.07%
EBIT Next 3Y48.62%
EBIT Next 5Y49.94%
FCF growth 1Y50.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.81%
OCF growth 3YN/A
OCF growth 5YN/A

ALVOTECH SA / ALVO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ALVOTECH SA (ALVO) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALVO.


What is the valuation status of ALVOTECH SA (ALVO) stock?

ChartMill assigns a valuation rating of 5 / 10 to ALVOTECH SA (ALVO). This can be considered as Fairly Valued.


What is the profitability of ALVO stock?

ALVOTECH SA (ALVO) has a profitability rating of 4 / 10.


How financially healthy is ALVOTECH SA?

The financial health rating of ALVOTECH SA (ALVO) is 1 / 10.